Abstract
The development and use of myeloid growth factors in support of cancer patients receiving chemotherapy has had a huge impact on the practice of oncology. While there are several areas of importance, this chapter will focus on the problem of chemotherapy-induced neutropenia and its impact on patient outcomes and potential strategies for management, including dose reduction, prophylactic antibiotics, and myeloid growth factors. In this context, the biology, pharmacology, and pharmacodynamics of myeloid growth factors will be reviewed, as well as the clinical evidence of benefit that have led to the current guidelines for use. Lastly, while the focus will be predominantly around support for chemotherapy-induced neutropenia, the impact of myeloid growth factors in other settings, including high-dose chemotherapy and the management of chronic neutropenia will also be briefly addressed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bodey G, Buckley M, Sathe Y, Freireich E. 1966; Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340.
Crawford J, Blackwell S. 2001. Hematopoietic growth factors. In:Perry MC The Chemotherapy Source Book,3rd.Lippincott Williams & Wilkins,Philadelphia:94–103.
Anderson N, Cella D, Calhoun E, et al. Rationale for the development of the FACT-N: a neutropenia-specific quality-of-life tool. Proceedings from the 2003 annual congress of the Oncology Nursing Society. Abstract 117.
Lyman G, Kuderer N, Green J, Balducci. 1998; The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857–1864.
Bonadonna G, Valagussa B, Moliterni A, Zambetti M, Brambilla C. 1995; Adjuvant Cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer — The results of 20 years of follow-up. N Engl J Med 332:901–906.
Budman D, Berry D, Cirrincione C, Henderson IC, Wood W, Weiss R, Rerree C, Muss H, Green M, Norton L, Frei E. 1998; Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205–1211.
Kwak L, Halpern J, Olshen, RHorning S. 1990; Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977.
Lyman G, Dale D, Crawford J. 2003; Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21: 4524–4531.
Lyman G, Dale D, Friedberg J, Crawford J, Risher R. 2004; Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22:4302–4311.
Moon S, Williams S, Cullen M. 2006; Role of prophylactic antibiotics in the prevention of infection after chemotherapy: a literature review. Support Cancer Ther 3:207–213.
Gafter-Gvili A, Fraser A, Mical P, Leibovici L. 2005; Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995.
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi M, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari M, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers G, Lauria F, Foa, RDel Favero A, 2005; the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987.
Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Hudddart R, Gollins S, Stanley A. 2005; Simple investigation in neutropenic individuals of the frequency of infection after chemotherapy +⁄− antibiotic in a number of tumours (SIGNIFICANT) Trial Group N Engl J Med353:988–998.
Tjan-Heijnen VCG, Postmus P, Ardizzoni A, Manegold C, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buccholz E, Biesma B, Legrand C, Debruyne C, Giaccone G. 2001; Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368.
Timmer-Bonte J, de Boo T, Smit H, Biesma B, Wischut F, Cheragwandi S, Termeer A, Hensing C, Akkermans J, Adang E, Bootsma G, Tjan-Heijnen V. 2005; Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 23:7974–7984.
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous V, Picozzi V, Rausch G, et al. 1991; Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325:164–170.
Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decaster G, Tomita D, et al. 1993; . Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 16A:319–324.
Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D. 1992; Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 80:1430–1436.
Blackwell S, Crawford J. 1994; G-CSF in the chemotherapy setting. In: . Morstyn, G. Granulocyte Colony-Stimulating Factor in the ClinicalMarcel Dekker, New York: 103–116.
Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shgan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. 2002; Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20:727–731.
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ. 2003; A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35.
ASCO 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Lyman G, Kuderer N, Djulbegovic B. 2002; Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. American Journal of Medicine 112:406–411.
National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. V.1.2007.
Lyman G: 2003; Risk assessment in oncology clinical practice: from risk factors to risk models. Oncology 17:8–13.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Crawford , J. (2009). Neutropenia. In: Ettinger, D.S. (eds) Supportive Care in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-291-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-59745-291-5_9
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-941-3
Online ISBN: 978-1-59745-291-5
eBook Packages: MedicineMedicine (R0)